[출처/시간] Briefing.com - 7:08 AM ET, 05/26/2026
Adcendo ApS announce that it has entered into a clinical trial collaboration and supply agreement with MSD. ADCE-T02, a potential best-in-class topoisomerase-1 (Topo-1) inhibitor-based ADC targeting Tissue Factor, will be evaluated in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in a new Phase Ib study in patients with advanced solid tumors.Under the terms of the Agreement, MSD will provide pembrolizumab to Adcendo, which will be the sponsor of the Phase Ib clinical combination trial. Adcendo and MSD each retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies.Adcendo anticipates dosing the first patient in the Phase Ib combination study in 2H 2026 and will investigate the safety, tolerability and preliminary efficacy of escalating doses of ADCE-T02 in combination with standard dose pembrolizumab in patients with advanced solid tumors.
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.